Sulfate Ester GI Compound for Motility and Pain Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for functional gastrointestinal disorders, such as irritable bowel syndrome, lack a comprehensive mechanism of action beyond spasmolytic activity and do not effectively address hypo- and hyperkinetic disorders of gastrointestinal motility, analgesic effects, and modulation of the enkephalinergic system.
Innovation Solution
Development of a novel compound, [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate, which interacts with aromatic sulfuric acid monoester through ion-exchange chromatography, providing improved pharmacological activity by regulating gastrointestinal motility and pain relief through opiate receptor modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing treatments for functional gastrointestinal disorders are used, then they provide basic spasmolytic activity, but they fail to effectively address hypo- and hyperkinetic disorders of gastrointestinal motility, analgesic effects, and modulation of the enkephalinergic system
Solution Approach 1:
The patent modifies the chemical structure of the active substance by creating a sulfate ester derivative of [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate. This structural parameter change results in a compound with enhanced pharmacological activity that can effectively address multiple aspects of functional gastrointestinal disorders including motility regulation, analgesia, and enkephalinergic system modulation
Solution Approach 2:
The invention creates a composite chemical structure by combining the active substance with sulfuric acid monoester, forming a novel sulfate ester compound. This composite structure integrates the pharmacological properties of the parent compound with the characteristics of the sulfuric acid ester, resulting in improved multi-faceted therapeutic activity
2Adaptability or versatility
If [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate is used, then it provides spasmolytic activity similar to mebeverine, but it does not provide comprehensive modulation of gastrointestinal motility and analgesic effects through opiate receptor agonism
Solution Approach 1:
The patent changes the pharmacological parameters of the compound by sulfating the phenolic hydroxyl group, which enhances the molecule's ability to interact with opioid receptors and the enkephalinergic system, thereby providing both spasmolytic and analgesic effects that the parent compound lacks
3Ease of manufacture
If acids such as acetic acid and benzoic acid are used to form salts with [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate, then salt formation is attempted, but thermodynamically stable solid salts are not formed due to the low acidity constant value pKBH+=6.25
Solution Approach 1:
The patent changes the chemical parameter of the acid component from weak organic acids (acetic acid, benzoic acid) to a stronger aromatic sulfuric acid monoester, which has sufficient acidity to form stable salts with the low-basicity amine, overcoming the thermodynamic instability issue
Solution Approach 2:
The invention creates a stable composite salt structure by combining the amine base with aromatic sulfuric acid monoester, forming a thermodynamically stable solid compound that overcomes the salt formation difficulties encountered with weaker acids
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compound effectively normalizes gastrointestinal motility, alleviates pain, and modulates enkephalinergic system function, offering enhanced treatment for a range of functional gastrointestinal disorders, including irritable bowel syndrome and visceral hypersensitivity.
Implementation Method 1
This salt can be produced when [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate interacts with a corresponding aromatic sulfuric acid monoester
Data Source
AI summary
The invention relates to the field of organic chemistry and pharmacy and provides a novel compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate, a method for treating and preventing functional gastrointestinal disorders, which comprises administering an effective amount of compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxy benzoate 4-methyl-2H-chromen-2-on-7-yl sulphate to a patient in need thereof, a pharmaceutical composition based on compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate, a drug comprising compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate, and a finished dosage form comprising compound [L-(dimethylamino)-2-phenybutyl ]-3,4,5 -trimethoxybenzoate 4-methyl-2H-chromen-2-on-7-yl sulphate. The invention further relates to the use of compound [2-(dimethylamino) phenylbutyl]-3,4,5-trimethoxy benzoate 4-methyl-2H-chromen-2-on-7-yl sulphate for treating and preventing functional gastrointestinal disorders.